# MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
Canonical URL: https://biopharmsignal.com/news/MGTX/meiragtx-to-present-3-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-2-3-radiation-induced-xerostomia-on-thursday-april-16-2026
Ticker: MGTX
Company: MeiraGTx
Source: MeiraGTx
Published: 2026-04-14 12:30 EST
Original Source URL: https://investors.meiragtx.com
## Summary

- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx

## Article Body
- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx
## Recent Company News
- 2026-07-07 11:30 EST — [MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-400-million-strategic-investment-by-oberland-capital-to-suppo-b21561a1) — Source: MeiraGTx
- 2026-05-14 20:30 EST — [MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: MeiraGTx
- 2026-05-14 12:00 EST — [MeiraGTx Reports First Quarter 2026 Financial and Operational Results](https://biopharmsignal.com/news/MGTX/meiragtx-reports-first-quarter-2026-financial-and-operational-results) — Source: MeiraGTx
- 2026-04-16 11:48 EST — [MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares](https://biopharmsignal.com/news/MGTX/meiragtx-announces-pricing-of-100-million-offering-of-ordinary-shares) — Source: MeiraGTx
- 2026-04-16 11:10 EST — [MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-the-acquisition-of-botaretigene-sparoparvovec-bota-vec-for-the-treatment-of-x-linked-retinitis-pigmentosa-xlrp) — Source: MeiraGTx
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)